Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several claims align with label-supported information (indications, HMG-CoA reductase mechanism, LDL-lowering, and muscle-related adverse effects). However, multiple claims about specific symptom categories (fatigue, muscle cramps, impaired flexibility, yoga exercise capacity) are not supported by the provided labeling excerpts, and the cardiovascular prevention claim is only partially supported by the excerpted indications (limited to risk reduction for specific cardiovascular outcomes rather than general “prevent cardiovascular disease”).
Category Scores
Accurate Statements
Lipitor (atorvastatin) is used to lower cholesterol levels.
Label indicates lipid-altering therapy as adjunct to diet for hypercholesterolemia/hyperlipidemia; and Mechanism of Action involves inhibition of HMG-CoA reductase (cholesterol biosynthesis rate-limiting step).
Lipitor (atorvastatin) works by inhibiting the production of the enzyme HMG-CoA reductase.
12.1 Mechanism of Action: “selective, competitive inhibitor of HMG-CoA reductase… rate-limiting step in cholesterol biosynthesis.”
By reducing cholesterol production, Lipitor (atorvastatin) helps lower LDL ("bad" cholesterol) levels.
Label includes treatment of hyperlipidemia and heterozygous/homozygous familial hypercholesterolemia; dosage section discusses starting doses based on LDL-C reduction (e.g., “large reduction in LDL-C”).
Unsupported Statements
Lipitor (atorvastatin) is used to prevent cardiovascular disease.
Provided indication excerpts describe reduction in specific outcomes (e.g., myocardial infarction, stroke, revascularization, angina) rather than a general statement to “prevent cardiovascular disease.”
Lipitor (atorvastatin) can cause muscle weakness, particularly in the arms and legs.
Label excerpt describes myopathy as muscle aches or muscle weakness with CPK elevation, but does not specify “particularly in the arms and legs.”
Lipitor (atorvastatin) can lead to fatigue.
Provided adverse reactions excerpts do not list fatigue/fatigue as an adverse reaction.
Lipitor (atorvastatin) can cause muscle cramps, particularly in the legs.
Provided label excerpts do not mention muscle cramps (or leg-specific cramps) as adverse reactions.
Lipitor (atorvastatin) may impair flexibility.
Provided label excerpts do not mention impaired flexibility.
Lipitor (atorvastatin) may increase fatigue.
Provided label excerpts do not mention fatigue.
Lipitor (atorvastatin) can affect muscle strength and endurance.
Label excerpt supports muscle weakness as part of myopathy, but does not mention “strength and endurance” as labeled adverse effects.
The impact of Lipitor (atorvastatin) on yoga exercise capacity is likely to be small.
Provided label excerpts contain no information about yoga or exercise capacity.
The impact of Lipitor (atorvastatin) on yoga exercise capacity may vary depending on individual factors such as age, sex, and overall health.
Provided label excerpts contain no information about yoga or exercise capacity stratified by age/sex/health.
Lipitor (atorvastatin) may reduce muscle strength, particularly in the arms and legs.
Label supports muscle weakness in myopathy but does not specify arm/leg or “particularly” distribution.
Lipitor (atorvastatin) may impair flexibility.
Provided label excerpts do not mention impaired flexibility.
Contradictions
Important Omissions
If discussing muscle-related adverse effects, the label excerpted concepts of rhabdomyolysis/myopathy should include that cases can occur (rare rhabdomyolysis with acute renal failure) and that therapy may be withheld/discontinued in serious acute conditions suggestive of myopathy, along with risk factors and monitoring (e.g., CPK elevation definition).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Some claims about muscle weakness are directionally consistent with myopathy, but several symptom- and activity-specific claims (fatigue, cramps, flexibility, yoga capacity) are unsupported by the provided excerpts, which could mislead about expected effects. The evaluation does not identify direct contradictions with the excerpts provided.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple unsupported or overly specific claims not present in the provided label excerpts (fatigue, muscle cramps, impaired flexibility, yoga exercise capacity; and arm/leg specificity). Cardiovascular prevention was stated broadly rather than as specific labeled risk reductions.
Suggested Improvement
Rephrase to match label-supported statements: (1) cardiovascular outcomes should be described as reductions in specific events (MI, stroke, revascularization, angina) as applicable; (2) muscle adverse effects should be limited to labeled myopathy/rhabdomyolysis concepts without unlabelled distribution (arm/leg) or non-supported symptoms (fatigue, cramps, flexibility); (3) remove yoga/exercise-capacity claims since no label support was provided.